Skip to main content
NewslettersWatchlist

Astrazeneca Plc ADR(AZN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low63.37
Day High64.31
Open:63.51
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

AstraZeneca shares fall on report of potential China probe fallout

The Anglo-Swedish company, which has invested heavily in the world’s No. 2 pharmaceuticals market, said last week that its China president, Leon Wang, was under investigation and that the drugmaker would cooperate with authorities
Reuters
AstraZeneca shares fall on report of potential China probe fallout
Motley Fool
3 Magnificent Stocks Under $100 to Buy in November
Motley Fool
3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever
Barchart
1 'Strong Buy' Penny Stock to Invest in AI Drug Development
Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Stock Target Advisor
Stock Market Analysis & News: October 7th, 2024
Motley Fool
Is Summit Therapeutics Stock a Buy?
Motley Fool
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
AllPennyStocks.com
Targeting Cancer's Achilles Heel: AI-Driven DDR Therapies Offer Hope
Yolowire
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives
Newswire.ca
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
Baystreet
AstraZeneca’s Stock Falls 5% As Cancer Drug Trial Disappoints
Motley Fool
3 Market-Beating Stocks to Buy for Less Than $100
Barchart
As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs
Motley Fool
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
Motley Fool
Why AstraZeneca Stock Is Sliding Today
Motley Fool
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
Reuters
AstraZeneca raises profit outlook on strong medicines demand
Motley Fool
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
Barchart
1 'Strong Buy' Biotech Stock With 132% Upside Potential
Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now

Profile

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.